AARVIK THERAPEUTICS
Live / Registered — Registered (as of 27 Jan 2026)
What this means for you
Registered since 27 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90879874
- Registration number
- 8118566
- Mark type
- Stylized text
- Filed
- 12 Aug 2021
- Published for opposition
- 31 May 2022
- Registered
- 27 Jan 2026
- Attorney of record
- Christopher D. Olszyk, Jr.
Goods and services
- Class 042 — Scientific and technological services: Scientific research for medical purposes in the field of cancer, infectious and neurologic diseases and disorders; research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of mono-specific antibodies, bi-specific, multi-specific antibodies; antibody-drug conjugates, T cell, NK cell, and Macrophage engaging antibodies; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, infectious and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research development and establishment of testing specifications and procedures in the field of cancer research, and scientific research in the field of cancer diagnosis and treatment; Providing scientific research information in the field of cancer research, and providing scientific research information in the field of cancer diagnosis and treatment
Owner
- Aarvik Therapeutics, Inc., Hayward, CA, US
- Aarvik Therapeutics, Inc., Hayward, CA, US
- Aarvik Therapeutics, Inc., Fremont, CA, US
Prosecution history
- 27 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 27 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 02 Jan 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 02 Jan 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 27 Dec 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Dec 2025 — USE AMENDMENT FILED
- 01 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
- 21 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Oct 2025 — SOU EXTENSION 5 GRANTED
- 28 May 2025 — SOU EXTENSION 5 FILED
- 21 Oct 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 29 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Nov 2024 — SOU EXTENSION 4 GRANTED
- 29 Nov 2024 — SOU EXTENSION 4 FILED